Cost-effectiveness of Screening of Hepatocellular Carcinoma under the Condition of Interferon Therapy for the Patients of Hepatitis C Virus Infection
Cost-effectiveness of Screening of Hepatocellular Carcinoma under the Condition of Interferon Therapy for the Patients of Hepatitis C Virus Infection
批准号:
15390166
负责人:
INOUE Yuji
金额:
$4.61万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2005
中文摘要
1.肝细胞癌定期筛查的效果:对肝癌患者门诊就诊规律进行回顾性调查后发现,定期就诊的患者所检出的肝癌体积明显小于不定期就诊的患者。COX比例风险分析结果显示,肿瘤直径小于20 mm的患者的生存情况明显好于肿瘤直径大于20 mm的患者。2.定期筛查试验在接受干扰素治疗的患者中的成本效果:我们结合丙型肝炎的自然病史和定期筛查和干扰素治疗的效果,建立了马尔可夫模型。对初始慢性肝炎状态的典型队列的模型模拟结果显示,与非SCRE…相比,周期性筛查试验的边际成本-效果比如果定期筛查能发现直径小于20 mm的肝细胞癌,即使接受干扰素治疗的慢性肝炎患者,也会更多地落在国际共识的范围内。3.肝细胞癌住院费用估算:对因肝细胞癌住院患者的住院费用进行回顾性调查,并进行统计学分析。多因素分析的结果是,一个由几个医疗干预变量组成的模型:手术切除、化疗-碘油治疗和亲代抗癌药物注射、并发症、腹水和浮肿、静脉曲张出血以及住院时间。对验证后的数据集进行相关系数高的住院费用预测。本研究建议该模型包含若干针对每个并发症或治疗的特定医疗干预措施,可以适当地估计住院患者的成本。4.针对不同肝癌阶段的干预措施的成本-效果模型的评估:我们创建了一个状态转移马尔可夫模型,该模型代表了慢性肝炎、肝硬变和失代偿性肝硬变合并或不合并肝癌的主要健康状态。我们假设治疗的选择符合肝癌的状态特征,如最大大小、个数和位置,治疗应从切除或局部消融开始,包括PEI和RFA,随着肝癌的进展,将采用局部消融加肝动脉化疗栓塞术(TACE)、TACE、肝动脉插管化疗(HAIC)和保守治疗。将其应用于孤立性小肝癌治疗的成本-效果评价时,预测的存活率与本研究所样本人群和日本全国调查的结果一致。较少
英文摘要
We could obtain the following results by this research grant.1.The effect of periodic screening test for hepatocellular carcinoma (HCC) : After conducting the retrospective survey of the regularity in pattern of outpatients visits for the HCC patients, the size of HCC detected in the patients with the regular office visit significantly smaller than those with irregular office visit. The results from the Cox-proportional hazard analysis showed the survival of the patients with tumor less than 20mm in diameter would be better significantly than those with tumor more than 20mm.2.Cost-effectiveness of periodic screening test for HCC in patients received interferon therapy : we made the Markov model combined the natural history of type C hepatitis and the effect of the periodic screening and interferon therapy. The result of model simulation for typical cohort with initially chronic hepatitis state revealed the marginal cost-effectiveness ratio of the periodic screening test versus non-scre … More ening would fall in the range of international consensus even the patients received the interferon therapy for chronic hepatitis if the periodic screening could detect the HCC less than 20mm in its diameter.3.The estimation of inpatient cost for HCC : The inpatients cost of patients hospitalized due to HCC was surveyed retrospectively and analyzed statistically. As a result of multivariate analysis, a model consisted of several variables of medical intervention ; resection, chemo-lipiodol therapy and parental anticancer agent injection, and complication ; ascites and edema, and variceal bleeding in addition to the period of hospitalization was obtained. It predicted inpatient cost with the high correlation coefficient for the validation dataset. This study suggested that the model consisted of several specific medical interventions corresponding to each complication or treatment could estimate the inpatients cost appropriately4.Evaluation of a cost-effectiveness model for the interventions to the different HCC stage : we created a state-transition Markov model which represented the principal health states of chronic hepatitis, cirrhosis, and decompensated cirrhosis with or without HCC. We assumed that the treatment choice corresponded to HCC state features such as maximal size, number and location, that treatment would start with resection or local ablation, including PEI and RFA, and that, as HCC progressed, local ablation plus transarterial chemoembolization (TACE), TACE, hepatic arterial infusion chemotherapy (HAIC) and conservative treatment would be applied. When it was applied for the evaluation of the cost-effectiveness of the treatments for solitary small HCC, the predicted survival rate was consistent with those of a sample population at our institution and of a nationwide survey of Japan. Less
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
病態別・治療別の肝細胞癌の医療費推定の試み
尝试根据疾病状态和治疗估算肝细胞癌的医疗费用
DOI:
--
发表时间:
2005
期刊:
医療情報学 (in press)
影响因子:
--
作者:
[Haku Ishida, Y Takemura, 石田 博]
通讯作者:
石田 博
Construction of a Web-Based System that Collects and Provides Essential Information from Diagnosis-Related Articles
构建一个基于网络的系统,从诊断相关文章中收集和提供基本信息
DOI:
--
发表时间:
2004
期刊:
Japan Journal of Medical Infomatics 24・1
影响因子:
--
作者:
[Haku Ishida, Y Takemura, 石田 博, Haku Ishida]
通讯作者:
Haku Ishida
High-Sensitivity C-Reactive Protein : Applications to Pediatrics
高灵敏度 C 反应蛋白:在儿科中的应用
DOI:
--
发表时间:
2003
期刊:
Lab Medica International Jan-Feb
影响因子:
--
作者:
[Haku Ishida, Y Takemura, 石田 博, Haku Ishida, 石田 博, Yuzuru Takemura]
通讯作者:
Yuzuru Takemura
Cost-effectiveness of surgical resection compared with local ablation for initial treatment of solitary small hepatocellular carcinoma with HCV hepatitis or cirrhosis
手术切除与局部消融治疗合并 HCV 肝炎或肝硬化的孤立性小肝细胞癌初始治疗的成本效益
DOI:
--
发表时间:
2005
期刊:
Japan Journal of Medical Informatics 25・Suppl
影响因子:
--
作者:
[Haku Ishida]
通讯作者:
Haku Ishida
地域医療連携をはかるためのシステムの構築
构建区域医疗合作体系
DOI:
--
发表时间:
2004
期刊:
日本臨床検査自動化学会会誌 29・153
影响因子:
--
作者:
[Haku Ishida, Y Takemura, 石田 博, Haku Ishida, 石田 博]
通讯作者:
石田 博
共 7 条
Diagnostic Performances and Cost-effectiveness of Screening Programs for Hepatitis C Virus-related Hepatocellular Carcinoma
-
批准号:20390152
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.15万
-
财政年份:2008
-
负责人:INOUE Yuji
-
依托单位:
Details of cost-Effectiveness of Interferon-alfa Therapy in Patients with Mile Chronic Hepatitis C.Compared by difference of clinical process between Japanese and American Patients.
-
批准号:09672302
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.98万
-
财政年份:1997
-
负责人:INOUE Yuji
-
依托单位:
Assessment of guideline for laboratory use using the method of decision science
-
批准号:04671436
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.28万
-
财政年份:1992
-
负责人:INOUE Yuji
-
依托单位:
海外基金